A New Inhaled Drug Enters Testing, a Fat-Protein Finding Surprises Researchers, and Our Own Software Explores 134 Drug Combinations
October 12 to 19, 2026 · Active week
This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.
The week in plain words
This week a brand-new Phase 1 trial opened to test an inhaled drug called CHF10073 in people with IPF. The WISPer trial testing MTX-463 finished enrolling patients and moved into its active treatment phase. A study on a protein called FABP5 caught our attention for showing that fat metabolism inside lung cells may play a bigger role in fibrosis than previously thought. None of this changes what is available to patients today, and IPF still has no cure.
Where things stand now
IPF remains a serious, progressive disease with no cure. Existing approved treatments slow the scarring of the lungs but do not reverse or undo damage that has already occurred. The two longest-standing anti-fibrotic pills, pirfenidone and nintedanib, are still widely used. Nerandomilast, approved by the FDA in October 2025, is the newest approved option and works by targeting a different pathway. Inhaled treprostinil and admilparant are in late-stage Phase 3 trials with positive signals but are not yet approved. Everything else in the pipeline, including cell therapies, gene delivery, and combination approaches, is experimental and not available outside of clinical trials.
The best option right now
If you or someone you know has IPF, the most honest answer is this: the best option right now is a conversation with a specialist at an IPF center. Nerandomilast is the newest FDA-approved choice, approved October 2025, and it slows disease progression, but it does not heal scarred lung tissue. Pirfenidone and nintedanib also slow progression and have years of real-world use behind them. Inhaled treprostinil and admilparant look promising in trials but are not yet approved. No drug currently available stops IPF entirely or gives lungs back their lost function. Joining a clinical trial may open access to investigational treatments, and that conversation belongs with a doctor who knows the full picture of an individual patient.
How close are we to regeneration
True regeneration, meaning actually growing back healthy lung tissue to replace scar tissue, is a research goal, not an available treatment. The closest experimental ideas in the data involve clearing out old, worn-out cells called senescent cells using approaches like uPAR-CAR-T therapy, then trying to stimulate the lung's own stem cells to regrow. Another concept pairs a drug called RSPO3 with senolytics to expand the pool of cells that normally repair the air sacs. These are all preclinical or conceptual, meaning they have been tested in laboratory settings but have not been proven to work in people. Researchers are genuinely optimistic about the direction, but regeneration in humans with IPF is still years away from being a real option.
Study of the week
The study of the week comes from Yin, Lei, and Mai, published in International Immunopharmacology in 2026. It looked at a protein called FABP5, which stands for fatty acid binding protein 5. Think of FABP5 as a tiny shuttle inside lung cells that carries fat molecules around. The study found that when FABP5 is present and working properly in the cells that line the air sacs (called type II alveolar epithelial cells), it seems to protect against pulmonary fibrosis by keeping the cell's fat metabolism healthy. When fat handling inside these cells goes wrong, it may push them toward the kind of stress and damage that contributes to scarring. This is early-stage research and does not point to any treatment yet, but it opens an interesting question: could fixing fat metabolism in lung cells be a new target for future drugs? Worth watching.
What changed since last week
Two things changed in trial status this week. The WISPer trial (NCT06967805) testing MTX-463, a Phase 2 investigational drug for IPF, stopped recruiting new participants and moved into the active treatment phase, meaning enrolled patients are now receiving the drug and being monitored. A real-world study (NCT07743996) on the emotional and social experiences of patients taking anti-fibrotic therapy was marked as completed, so results from that study may be published in the coming months. A brand-new Phase 1 trial (NCT07876284) opened to test the safety and tolerability of an inhaled drug called CHF10073, which has not yet started recruiting. Twelve new scientific papers were added to the atlas across topics including immune cell profiling, a newly identified mechanical stress pathway in macrophages called PIEZO1, single-cell genomics, yoga as a quality-of-life intervention, and stem cell scaffold research.
Our own search for a cure this week
Every day, PF-Atlas runs its own in-house discovery engine, a genetic-algorithm solver combined with an AI literature scanner. This is our own software, not findings from outside research groups. The solver does not test drugs in a lab or in people. Instead, it simulates combinations of existing, already-approved or already-known drugs, including drugs borrowed from completely different diseases, to look for cocktails that a computer model predicts could be helpful for IPF. These are computer-generated hypotheses that guide which ideas researchers should look at next. They are not proven treatments and have not been tested in clinical trials. This week our solver ran 134 combination simulations and generated 106 cross-disease ideas and 2 formal hypotheses. The cross-disease ideas this week came from an unexpected direction: spinal cord injury research. An enzyme called ChABC (Chondroitinase ABC), which is being studied for breaking down scar tissue in the spinal cord, showed up repeatedly in our solver as a potential candidate for breaking down the abnormal protein mesh (called ECM, or extracellular matrix) that stiffens fibrotic lungs. Our software generated multiple hypotheses pairing inhaled or airway-delivered ChABC with other agents like mesenchymal stem cells, macrophage-shifting therapies, or anti-TGF-beta drugs. Again, these are computer-generated ideas, not treatments. The solver's top-scoring formula this week combined five agents: wnt-rspo3, an ECM remodeling inhibitor, a HOPX activator, curcumin targeted at the TLR4-NLRP3 inflammation pathway, and a miR-34a inhibitor, with a predicted FVC score of 99 in the model. FVC is a measure of lung capacity. That number is the model's internal score, not a result from a human trial. Other candidates flagged this week as novel solver breakthroughs include inhaled recombinant human BMP4, a protein called AGER-ECD-Fc that may help guide lung cells toward a healthier type, an Apelin-13 receptor agonist, Yoda1 as an inhaled PIEZO1 activator (interesting given this week's paper on the PIEZO1 pathway in macrophages), and recombinant human KGF-2. New additions to the solver's candidate pool include curcumin and an ECM remodeling agent targeting enzymes called MMPs and TIMPs. All of this is our own software output, clearly labeled as hypothetical and computational, shared here to be transparent about how we search for new directions every single week.
Inside the PF-Atlas lab
- Inhaled Recombinant Human BMP4 (rhBMP4)
- Recombinant AGER (RAGE) Extracellular Domain Fusion / AEC1 Fate Inducer (AGER-ECD-Fc)
- Apelin-13 / APJ Receptor Agonist (MLN-0905 analog)
- Yoda1 (Inhaled PIEZO1 Agonist)
- Recombinant Human KGF-2 (FGF-7 isoform / Repifermin)
- Spinal Cord Injury → IPF: Recombinant ChABC (enzymatic scar remodeling) + mesenchymal stem cell or alveolar progenitor co-transplantation to restore epithelial-mesenchymal communication
- Spinal cord injury → IPF: Inhaled or intra-tracheal ChABC (or engineered variants with improved stability/half-life) combined with simultaneous macrophage polarization therapy (IL-4/IL-13 receptor antagonists like dupilumab or fesomersen) to shift pro-fibrotic M2 macrophages toward anti-fibrotic M1 phenotype
- Spinal Cord Injury → IPF: ChABC (Chondroitinase ABC) engineered with improved half-life + bone marrow-derived mesenchymal stem cells (BMSCs) expressing anti-fibrotic factors (BMP7, HGF) delivered via inhalation or minimally invasive intrapulmonary injection
- Spinal Cord Injury → IPF: Intratracheal delivery of ChABC (engineered for lung stability) combined with mesenchymal stem cells secreting anti-fibrotic cytokines (IL-10, TGF-β inhibitors). Phase 1 trials launching 2025 for SCI; pulmonary adaptation would involve nebulized or bronchoscopic administration.
- Spinal cord injury → IPF: Intratracheal or nebulized recombinant ChABC (being developed for SCI in Phase 1/2 trials) adapted as a direct ECM-remodeling agent combined with anti-TGF-β checkpoint inhibitors
- If we combine pirfenidone + curcumin_tlr4_nlrp3 + nmn_nad, then chronic smoke-in
- If we combine nerve regeneration support (KGF + FGF10) with senolytic clearance
Everything here is PF-Atlas computer model output, a hypothesis to guide researchers. It is not clinical evidence and not a treatment anyone can take.
Sources this week
- WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) · status: RECRUITING → ACTIVE_NOT_RECRUITING NCT06967805 on ClinicalTrials.gov ↗
- Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study · status: RECRUITING → COMPLETED NCT07743996 on ClinicalTrials.gov ↗
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary Fibrosis · new trial NCT07876284 on ClinicalTrials.gov ↗
- Connective tissue disease-associated interstitial lung disease: immune profiling and correlation of immune cells with pulmonary function in SSc-ILD. · Annals of medicine 2026 PMID 42876296 on PubMed ↗
- The PIEZO1/CISD1/IP3R Mechanotransduction Axis Drives Macrophage Mitochondrial Dysfunction and Inflammatory Activation in Pulmonary Fibrosis. · MedComm 2026 PMID 42889684 on PubMed ↗
- Single-cell multi-omics in IPF and COPD: from atlas to impact. · The European respiratory journal 2026 PMID 42880940 on PubMed ↗
- Low-dose vs standard-dose photon-counting CT for myopathy-associated interstitial lung disease: a prospective feasibility study. · European radiology 2026 PMID 42878810 on PubMed ↗
- Quantitative assessment of fibroelastosis reveals distinct elastic and collagen fiber patterns in idiopathic and secondary pleuroparenchymal fibroelastosis. · Virchows Archiv : an international journal of pathology 2026 PMID 42878800 on PubMed ↗
- Inhalation therapies in interstitial lung diseases. · Expert opinion on drug delivery 2026 PMID 42858239 on PubMed ↗
- FABP5 attenuates pulmonary fibrosis by regulating lipid metabolism in type II alveolar epithelial cells. · International immunopharmacology 2026 PMID 42537352 on PubMed ↗
- Structure based identification of novel 4,5,6,7-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one derivatives as nonacidic ATX inhibitors with promising antifibrotic effects. · European journal of medicinal chemistry 2026 PMID 42224938 on PubMed ↗
- The Safety and Efficacy of a Transbronchial Lung Cryobiopsy Using a 1.7-mm Cryoprobe in Older Adult Patients with Suspected Interstitial Lung Disease: A Single-center, Retrospective, Observational Study. · Internal medicine (Tokyo, Japan) 2026 PMID 41780974 on PubMed ↗
- Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis (YES-IPF). · Respiratory medicine 2026 PMID 42874938 on PubMed ↗
- Dynamic tensile conditioning of mesenchymal stem cell-laden auxetic scaffolds for enhanced YAP-dependent miR-30 enrichment in extracellular vesicles for pulmonary fibrosis therapy. · Biomaterials 2026 PMID 42880081 on PubMed ↗
- Nedd4L-mediated stabilization of morphogenetic protein receptor 2 in lung fibroblasts confers protection against pulmonary fibrosis. · Signal transduction and targeted therapy 2026 PMID 42864328 on PubMed ↗
- Identification of priority gaseous component in biodiesel exhaust and its potential pulmonary hazards: a data-driven screening and validation strategy. · Environment international 2026 PMID 42892262 on PubMed ↗
- Integrated transcriptomic and experimental analyses identify SRPK1/SRSF1 as a therapeutically relevant splicing regulatory axis in pulmonary fibrosis. · Cellular signalling 2026 PMID 42863731 on PubMed ↗
- Integrated UPLC-Q-Orbitrap-MS/MS, network pharmacology, and in vivo evaluation reveal bioactive constituents and mechanisms of Bushen Tongluo Decoction against idiopathic pulmonary fibrosis. · Journal of pharmaceutical and biomedical analysis 2026 PMID 42887381 on PubMed ↗
- Serial multidomain six-minute walk assessment for dynamic risk prediction in idiopathic pulmonary fibrosis. · American journal of respiratory and critical care medicine 2026 PMID 42860051 on PubMed ↗
- "Interstitial lung disease with associated severe pulmonary hypertension is rarely idiopathic by clinical or pathologic measures". · The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2026 PMID 42858771 on PubMed ↗
- Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF. · BMJ open respiratory research 2026 PMID 42869508 on PubMed ↗
- Toward molecular endotypes of CLAD: dancing around the truth hidden in the tissue. · The European respiratory journal 2026 PMID 42855186 on PubMed ↗
- Effects of combination metformin and nintedanib therapy in a mouse model of irradiation-induced pulmonary fibrosis. · Journal of radiation research 2026 PMID 42502979 on PubMed ↗
This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.